MultiCell Technologies, Inc. (MCET) spiked last Monday after a press release came out, announcing the company had been granted a U.S. patent covering novel drug compositions and platform technologies used for fighting virus infection and cancer. MCET climbed by 57% in price on a 750 thousand share volume at a $846,1 thousand trade value. These were the highest numbers for the company in over five months and the first significant increase since late March.
The next day, however, the ticker suffered... more
On Thursday, Bergio International, Inc. (BRGO) managed to timely submit its 10-Q for the period ended June 30, 2014. The next day, BRGO issued a press release in which it commented on the results from the report. As can be seen in the filing, the financials did not account for much progress made by the company:
Cash: $65,1 thousand
Total current assets: $2,1 million
Total current liabilities: $879,1 thousand
Revenues: $361,1 thousand
Net loss: $580,1 thousand
In the press release from August 15, BRGO... more
Puramed Bioscience, Inc. (PMBS) ended last week with a slide down, lowering the price back to the $0.0001 mark. PMBS's efforts have had no success in maintaining a long-lasting interest in the company. The price of PMBS' stock has been low throughout recent events. The announcements about the company's plans for future development have been insufficient to halt the decline.
PMBS' downfall began after an 8-K issued on July 11 reported about a number of decisions that shareholders seemingly did not approve... more
The efforts mPhase Technologies, Inc. (XDSL) has made to attract investors' interest lately have had no reaction on the market. XDSL recently reported a growth in revenues in the last quarter of its fiscal year ended June 30, 2014. The company stated in a press release issued on August 5 that its revenues have grown by approximately 6% compared to the previous quarter.
We can take a look at XDSL's 10-Q for the period ended March 31, 2014 to see what this would translate into:
Cash: $87,4 thousand